Márta Korbonits, MD, PhD, the 2023 Endocrine Society Gerald D. Aurbach Laureate Award recipient for Outstanding Translational Research, talks to Endocrine News about the award, her research on pituitary adenomas, and her own words of wisdom. Márta Korbonits, MD, PhD, is no stranger to the endocrine research community. As president of the Society for Endocrinology... Márta Korbonits, MD, PhD, the 2023 Endocrine Society Gerald D. Aurbach Laureate Award recipient for Outstanding Translational Research, talks to Endocrine News about the award, her research on pituitary adenomas, and her own words of wisdom. Márta Korbonits, MD, PhD, is no stranger to the endocrine research community. As president of the Society for Endocrinology...
As the weather in the Washington D.C., area starts ebbing from shorts and T-shirts to jeans and hoodies, Autumn signals its arrival and therefore, the focus of Endocrine News turns to our annual diabetes research and practice issue each November, to coincide with Diabetes Awareness Month. As usual, thanks to the plethora of research on...
Hypoglycemia from overtreatment is a serious but seldom recognized complication in older adults with type 2 diabetes. A new decision support tool developed by the Endocrine Society can help primary care providers avoid overtreatment and cut the risk of hypoglycemic events in these patients. The use of a clinical decision support tool can reduce the risk...
More than 100 years after the discovery of insulin galvanized our field, diabetes research and care remain a central part of endocrinology. Diabetes Awareness Month offers the opportunity to reflect on the importance of our research and clinical care to millions of people around the globe. For the 540 million people worldwide living with diabetes,...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * FDA Approves Lilly’s Zepbound™ (tirzepatide) for Chronic Weight Management On November 8, the U.S. Food and Drug Administration (FDA) approved Eli Lilly and Company’s (NYSE: LLY) Zepbound™ (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP (glucose-dependent insulinotropic polypeptide)...